Table 3 Defining Characteristics of Retroviral Infection in Humanized Mouse Models
From: The utilization of humanized mouse models for the study of human retroviral infections
Model | Strain of Virus | Method of Infection | Active Viremia (after how long) | Infected Tissues | Depletion of T Cells? | Neutralizing Ab? |
|---|---|---|---|---|---|---|
SCID-hu Thy/Liv | HIV-1 (R5, X4) | IV or intraorgan | Within a few weeks | CD4+ T and myelomonocytic cells | Yes | No |
hu-PBL SCID | HIV-1 (R5, X4) | IP or intraorgan | Within 2 weeks | T cells, vaginal | Yes | Yes |
NOD SCID BLT | HIV-1 (R5) | IP, vaginal, rectal | Within a few weeks | Vaginal, rectal, GALT | Yes | Yes |
NOD SCID IL2r γ-/- | HIV-1 (R5, X4) | IP, IV | Within a few weeks | Peripheral blood, spleen, bone marrow, thymus, vaginal | Yes | Yes |
Rag2-/-γc-/- | HIV-1 (R5, X4) | IP, vaginal, rectal | Within 2 weeks | Peripheral blood, thymic, splenic, and lymphoid tissues, vaginal and rectal mucosa | Yes | Yes |
NOD SCID β2m | HTLV-1 (transformed cell lines) | IP, IV | Between 3 and 12 weeks | Peripheral blood, spleen, lymph nodes, bone marrow | N/A | N/A |
NOD SCID IL2rγ null ("NOG") | HTLV-1 (transformed cell lines) | IP, IV | Within 2 weeks | Peritoneal cavity, spleen, peripheral blood | N/A | N/A |